Lilly wagers almost $1B on Rigel's drugs for immune and nervous systems
Bio Pharma Dive
FEBRUARY 18, 2021
For $125 million up front, Lilly secures rights to a drug about to enter mid-stage testing for autoimmune and inflammatory diseases, as well as preclinical assets targeting the central nervous system.
Let's personalize your content